ArticlePloS one2019
Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Efficacy of chemotherapy for lymph node-positive luminal A subtype breast cancer patients: an updated meta-analysis.World journal of surgical oncology · 2020Pooled it
- Niclosamide-Modulated Apoptosis and Autophagy in Breast Cancer Cells via Phosphorylated JNK as a Common Regulator.International journal of medical sciences · 2025Article
- CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.Frontiers in immunology · 2024Review
- Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution.Surgery open science · 2023Article
- Neutrophil-to-lymphocyte ratio is a negative prognostic biomarker for luminal A breast cancer.Gland surgery · 2023Article
- 18β-glycyrrhetinic Acid Modulated Autophagy is Cytotoxic to Breast Cancer Cells.International journal of medical sciences · 2023Article
- Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy-results from the prospective multi-center BRENDA II study.Breast cancer (Tokyo, Japan) · 2022Article
- Luminal A Breast Cancer: How Feasible is Omitting Axillary Dissection Without Neoadjuvant Therapy.The breast journal · 2022Article
- Nomograms predict survival of patients with lymph node-positive, luminal a breast cancer.BMC cancer · 2021Article
- The Signal Transducer IL6ST (gp130) as a Predictive and Prognostic Biomarker in Breast Cancer.Journal of personalized medicine · 2021Review
- Article
- Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches.Breast cancer : basic and clinical research · 2021Review
- Landmark trials in the medical oncology management of early stage breast cancer.Seminars in oncology · 2020Review
- Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia.World journal of surgical oncology · 2020Observational
- Nodal positivity decreases with age in women with early-stage, hormone receptor-positive breast cancer.Cancer · 2020Article
- Impact of deviation from guideline recommended treatment on breast cancer survival in Asia.Scientific reports · 2020Article
- Establishment and Validation of Novel Clinical Prognosis Nomograms for Luminal A Breast Cancer Patients with Bone Metastasis.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study based on the BRENDA data, we investigated the impact of endocrine ± chemotherapy for luminal A, nodal positive breast cancer on recurrence free (RFS) and overall survival (OS). In addition, we analysed if tumor size of luminal A breast cancer influences survival in patients with the same number of positive lymph nodes.
methodsIn this retrospective multi-centre cohort study data of 1376 nodal-positive patients with primary diagnosis of luminal A breast cancer during 2001-2008 were analysed. The results were stratified by therapy and adjusted by age, tumor size and number of affected lymph nodes.
resultsIn our study population, patients had a good to excellent prognosis (5-year RFS: 91% and tumorspecific 5-year OS 96.5%). There was no significant difference in RFS stratified by patients with only endocrine therapy and with endocrine plus chemo-therapy. Patients with 1-3 affected lymph nodes had no significant differences in OS treated only with endocrine therapy or with endocrine plus chemotherapy, independent of tumor size. Patients with large tumors and more than 3 affected lymph nodes had a significant worse survival as compared to the small tumors. However, despite the worse prognosis of those, adjuvant chemotherapy failed in order to improve RFS.
conclusionsAccording to our data, nodal positive patients with luminal A breast cancer have, if any, a limited benefit of adjuvant chemotherapy. Tumor size and nodal status seem to be of prognostic value in terms of survival, however both tumor size as well as nodal status were not predictive for a benefit of adjuvant chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.